AbbVie stock draws a Moderate Buy consensus from 31 brokers
AD HOC NEWS
AbbVie Inc. stock has garnered a "Moderate Buy" consensus from 31 brokerages, with an average one-year target of USD 272.66. This positive outlook is supported by its strong Q2 2026 revenue growth of 10.20% and an adjusted EPS beat, although its full-year EPS guidance midpoint is slightly below consensus. The company's stock is currently trading near its 52-week high, with its next earnings report expected on October 23, 2026.
Read the full story
This is a short summary. The complete article is published by AD HOC NEWS.
Headline and summary aggregated from public news feeds. For information only — not financial advice.